RxDoctor Payments Data

Jian Lin, MD

Neurology · Bakersfield, CANPI 1982683959

Payments from drug & device makers

$23,172in general payments, 2019–2025

Across 1,156 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Biogen$2K
  • UCB, Inc.$1K
  • Novartis$1K
  • EMD Serono, Inc.$955
  • Neurelis, Inc.$880
  • plus $14K from 54 others

What the payments were for

  • Speaking & faculty fees$680%
  • Food & beverage$22,79998%
  • Education$3051%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)270$3,207
Biogen61$1,512
UCB, Inc.60$1,475
Novartis78$1,339
EMD Serono, Inc.43$955
Neurelis, Inc.39$880
Teva Pharmaceuticals USA, Inc.41$824
Neurocrine Biosciences, Inc.20$725
Sunovion Pharmaceuticals Inc.36$684
Merz Pharmaceuticals, LLC29$681
Amgen(2 entities)28$612
AstraZeneca(2 entities)33$599
Kyowa Kirin, Inc.24$513
Merz North America, Inc.18$500
Alnylam Pharmaceuticals Inc.17$499
Lilly USA, LLC26$489
Akcea Therapeutics, Inc.10$441
Eisai Inc.18$437
Acadia Pharmaceuticals Inc22$404
Supernus Pharmaceuticals, Inc.20$385
SK Life Science, Inc.20$377
Argenx US, Inc.12$349
Acorda Therapeutics, Inc16$328
Sanofi11$318
MDD US Operations, LLC11$313
Ipsen Biopharmaceuticals, Inc19$311
Pfizer15$290
Adamas Pharmaceuticals, Inc.13$289
Lundbeck LLC8$276
Sumitomo Pharma America, Inc.16$264
Takeda Pharmaceuticals U.S.A., Inc.12$238
Biohaven Pharmaceutical Holding Company Ltd.8$231
Abbott5$214
Impel Pharmaceuticals Inc.3$206
Biohaven Pharmaceuticals, Inc.10$166
Genentech USA, Inc.6$164
ANI Pharmaceuticals, Inc.7$139
Jazz Pharmaceuticals Inc.3$136
Vanda Pharmaceuticals Inc.4$104
Johnson & Johnson(3 entities)5$100
TG Therapeutics, Inc.4$100
Janssen Scientific Affairs, LLC1$88
Scilex Pharmaceuticals Inc.5$86
Avanir Pharmaceuticals, Inc.5$82
Sanofi-aventis U.S. LLC4$80
Boston Scientific3$78
GRT US Holding, Inc.2$59
Zogenix Inc.3$58
Amneal Pharmaceuticals LLC3$57
Otsuka America Pharmaceutical, Inc.3$53
Sarepta Therapeutics, Inc.2$52
Mallinckrodt Enterprises LLC3$51
E.r. Squibb & Sons, L.L.C.3$50
Amylyx Pharmaceuticals, Inc.3$49
Bristol Myers Squibb3$47
Greenwich Biosciences, Inc.2$45
Tanabe Pharma America, Inc.2$34
CSL Behring2$33
Banner Life Sciences, LLC2$31
Catalyst Pharmaceuticals, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,172 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$294,133
Medicare patients
485
Services billed
11,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FinteplaFenfluramine Hcl13$213,500
IngrezzaValbenazine Tosylate12$95,128
CopaxoneGlatiramer Acetate11$65,509
AptiomEslicarbazepine Acetate34$61,363
NourianzIstradefylline16$46,672
VimpatLacosamide20$27,395
Rufinamide30$24,065
Levetiracetam526$20,365
NamzaricMemantine Hcl/Donepezil Hcl13$17,590
Nurtec OdtRimegepant Sulfate11$13,160
UbrelvyUbrogepant12$12,094
Memantine Hcl494$11,997
Aimovig AutoinjectorErenumab-Aooe16$11,564
Teriflunomide17$11,553
Carbidopa-LevodopaCarbidopa/Levodopa344$9,118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Fintepla, Vimpat$1,475$240,89533 claims
Neurocrine Biosciences, Inc.Ingrezza$725$95,12812 claims
Teva Pharmaceuticals USA, Inc.Copaxone$824$65,50911 claims
Sunovion Pharmaceuticals Inc.Aptiom$684$61,36334 claims
Kyowa Kirin, Inc.Nourianz$513$46,67216 claims
AbbVieNamzaric, Ubrelvy$3,207$29,68425 claims
PfizerNurtec Odt$290$13,16011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →